Proteases and protease inhibitors in infectious diseases

  title={Proteases and protease inhibitors in infectious diseases},
  author={Ayodeji A. Agbowuro and Wilhelmina May Huston and Allan B. Gamble and Joel D. A. Tyndall},
  journal={Medicinal Research Reviews},
  pages={1295 - 1331}
There are numerous proteases of pathogenic organisms that are currently targeted for therapeutic intervention along with many that are seen as potential drug targets. This review discusses the chemical and biological makeup of some key druggable proteases expressed by the five major classes of disease causing agents, namely bacteria, viruses, fungi, eukaryotes, and prions. While a few of these enzymes including HIV protease and HCV NS3‐4A protease have been targeted to a clinically useful level… 

From Naturally-Sourced Protease Inhibitors to New Treatments for Fungal Infections

Findings of protease inhibitors from environmental sources are highlighted, new opportunities for assessment of antifungal activity are proposed, and novel applications to combat biomedically-relevant fungal diseases with in vivo and clinical purpose are discussed.

Role of Anti-Viral Drugs in Combating SARS-CoV-2

The emanation of antiviral is generally the outcome about an appreciably expanded skills or proficiency of the generative, microscopic and atomic activity of organisms, allowing biomedical analyst to acknowledge the structure, mechanism of action and activity of viruses.

Inhibitory antibodies identify unique sites of therapeutic vulnerability in rhinovirus and other enteroviruses

It is shown that the regulatory role of 3C in enterovirus replication is another drug-targetable function besides its protease activity, and both single-chain antibody fragments target sites on the 3C protease that are distinct from its known drug site and possess different mechanisms of inhibition.

Tackling Pseudomonas aeruginosa Virulence by a Hydroxamic Acid-Based LasB Inhibitor.

The inhibition of LasB, a harmful zinc metalloprotease secreted by Pseudomonas aeruginosa, through a hydroxamate derivative is described and shown to restore the effect of the antimicrobial peptide LL-37, decrease the formation of P. aerug inosa biofilm and reduce the release of extracellular DNA.

Fungal Proteases as Emerging Biocatalysts to Meet the Current Challenges and Recent Developments in Biomedical Therapies: An Updated Review

It is concluded that hydrolysis of proteins in industries is one of the most significant applications of fungal enzymes that led to massive usage of proteomics.

Covalent Antiviral Agents.

This chapter reviews the structures, activities, and inhibition mechanisms of covalent inhibitors against severe acute respiratory syndrome coronavirus 2, dengue virus, enterovirus, hepatitis C virus, human immunodeficiency virus, and influenza viruses, and discusses the application of in silico study incovalent inhibitor design.

Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.

The drug design strategies of Protease Inhibitors, chemical and pharmacological characteristics of some mechanism based inhibitors, and the recent developments in small molecule based drug discovery with HIV Proteases as drug target are summarized.



New directions for protease inhibitors directed drug discovery

Drugs/drug candidates that target proteases, such as malarial plasmepsins, β‐secretase, virus protease, and dipeptidyl peptidase‐4 are described, as examples of drugs thattarget proteases.

Bacterial proteolytic complexes as therapeutic targets

The roles of the key prokaryotic degradative proteases are summarized, with a focus on the initial efforts and associated challenges in developing specific therapeutic modulators of these enzymes as novel classes of antibacterial drugs.

Protease inhibitors in the clinic.

The progress of protease inhibitors into man is assessed, the futures of these enzymes are predicted, and some of the hurdles that have been overcome and that still remain for this promising class of new therapeutic agents are outlined.

Inhibitors Selective for Mycobacterial versus Human Proteasomes

It is shown that certain oxathiazol-2-one compounds kill non-replicating M. tuberculosis and act as selective suicide-substrate inhibitors of the mycobacterial proteasome by cyclocarbonylating its active site threonine.

Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis.

The study of fungal biochemistry, physiology, and genetics has undergone a resurgence to new heights of activity, providing a framework on which to build drug discovery programs in several new areas, two of which will be discussed in detail: the biology of Candida albicans secreted aspartyl protease with respect to inhibitor discovery, evaluation, and possible clinical utility.

HIV protease inhibitors: a review of molecular selectivity and toxicity

From the chemical structures of HIV protease inhibitors and their possible off-target molecules, hints for optimizing the molecular selectivity of the inhibitors are obtained to provide help in the design of new compounds with enhanced bioavailability and reduced side effects.

Beta-lactones as specific inhibitors of ClpP attenuate the production of extracellular virulence factors of Staphylococcus aureus.

The most potent inhibitor was able to completely abolish hemolytic and proteolytic activities and showed a dramatic decrease in the activities of virulence associated lipases and DNases, emphasizing the potential value of such compounds.

HIV aspartyl protease inhibitors as promising compounds against Candida albicans

Cells of Candida albicans (C. albicans ) can invade humans and may lead to mucosal and skin infections or to deep-seated mycoses of almost all inner organs, especially in immunocompromised patients.


The natural inhibitors of streptokinase, already powerful in the majority of human sera, are stimulated by the parenteral administration of the agent, resulting in significant increase of resistance to its plasminogen activating ability.

Cysteine Proteases: Modes of Activation and Future Prospects as Pharmacological Targets

This review specifically highlights the modes of activation (processing) of papain family enzymes, which involve auto-activation, trans-activation and also clarifies the future aspects of targeting PPIs to prevent the activation of cysteine proteases.